Top Markets
#1 NEW X CEO IS BACK NEW X CEO IS BACK +210,975.57%
#2 Beta Finance Beta Finance +8,979.03%
#3 Tribe Tribe +73.83%
#4 Orochi Network Orochi Network +53.40%
#5 Chainbase Chainbase +40.85%
#6 BabyBoomToken BabyBoomToken +34.25%
#7 Block Street Block Street +31.59%
#8 Chrema Coin Chrema Coin +28.62%
#9 Freysa AI Freysa AI +26.78%
#10 B3 (Base) B3 (Base) +25.98%
Coin of the day
NEW X CEO IS BACK NEW X CEO IS BACK
Impostazioni
Lingua
ITALIANO
Valuta
USD
Tema
Nuformix plc Nuformix plc

Nuformix plc

NFX
Classifica tra le azioni #20651
Nuformix plc operates in the field of pharmaceutical development for treating... Nuformix plc operates in the field of pharmaceutical development for treating fibrosis and oncology through drug repurposing in the United Kingdom. It offers NXP001, which has completed Phase 1 for use in oncology supportive care. The company is also developing NXP004, a novel form of Olaparib, which is in the IP generation phase for treating oncology; and NXP002 that is in pre-clinical stage for the treatment of idiopathic pulmonary fibrosis. It also has an option agreement with Oxilio Ltd. for NXP001 for oncology indications. Nuformix plc was founded in 2008 and is based in London, the United Kingdom.
Prezzo delle azioni
$0.00244926
Capitalizzazione di mercato
$51.67K
Variazione (1 giorno)
5.88%
Variazione (1 anno)
110.15%
Paese
GB
Scambia Nuformix plc (NFX)

Categoria

Healthcare
Ricavi di Nuformix plc (NFX)
Ricavi nel Sep 2025 TTM: 0.00
Secondo gli ultimi rapporti finanziari di Nuformix plc, i ricavi attuali dell'azienda (TTM) sono pari a 0.00. Nel 2024, l'azienda ha registrato ricavi di 0.00 uguale a i ricavi dell'anno 2023, che erano pari a 0.00. I ricavi rappresentano l'importo totale generato dalla vendita di beni o servizi. A differenza degli utili, le spese non vengono detratte.
Storico dei ricavi per Nuformix plc da 2014 a 2026
Ricavi alla fine di ogni anno
Anno Ricavi Cambia
2026 (TTM) 0.00 0.00%
2025 0.00 0.00%
2024 0.00 0.00%
2023 0.00 -100.00%
2022 $65.73K -75.61%
2021 $269.56K -59.39%
2020 $663.79K -16.44%
2019 $794.35K 3,678.32%
2018 $21.02K 0.00%
2017 0.00 -100.00%
2016 $872.91K 181.15%
2014 $310.47K 0.00%
Ricavi di aziende simili o concorrenti
Azienda Ricavi Differenza nei ricavi Il paese
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B -
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B -
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B -
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B -
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.70B -
AU